Prelude Therapeutics Inc (NASDAQ: PRLD)’s stock price has dropped by -7.84 in relation to previous closing price of 0.81. Nevertheless, the company has seen a loss of -17.45% in its stock price over the last five trading days. globenewswire.com reported 2024-12-11 that • PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
Is It Worth Investing in Prelude Therapeutics Inc (NASDAQ: PRLD) Right Now?
The 36-month beta value for PRLD is at 1.41. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for PRLD is 27.22M, and currently, shorts hold a 11.40% of that float. The average trading volume for PRLD on February 28, 2025 was 423.28K shares.
PRLD’s Market Performance
The stock of Prelude Therapeutics Inc (PRLD) has seen a -17.45% decrease in the past week, with a -34.65% drop in the past month, and a -21.47% fall in the past quarter. The volatility ratio for the week is 7.53%, and the volatility levels for the past 30 days are at 8.75% for PRLD. The simple moving average for the past 20 days is -23.40% for PRLD’s stock, with a -73.05% simple moving average for the past 200 days.
Analysts’ Opinion of PRLD
Many brokerage firms have already submitted their reports for PRLD stocks, with H.C. Wainwright repeating the rating for PRLD by listing it as a “Buy.” The predicted price for PRLD in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on September 19, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see PRLD reach a price target of $3. The rating they have provided for PRLD stocks is “Underweight” according to the report published on June 20th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to PRLD, setting the target price at $7 in the report published on March 13th of the previous year.
PRLD Trading at -30.34% from the 50-Day Moving Average
After a stumble in the market that brought PRLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.04% of loss for the given period.
Volatility was left at 8.75%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares sank -34.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.84% lower at present.
During the last 5 trading sessions, PRLD fell by -17.45%, which changed the moving average for the period of 200-days by -81.70% in comparison to the 20-day moving average, which settled at $0.9725. In addition, Prelude Therapeutics Inc saw -41.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRLD starting from Vaddi Krishna, who purchase 5,000 shares at the price of $1.21 back on Dec 31 ’24. After this action, Vaddi Krishna now owns 142,553 shares of Prelude Therapeutics Inc, valued at $6,044 using the latest closing price.
Vaddi Krishna, the CEO of Prelude Therapeutics Inc, purchase 10,000 shares at $1.20 during a trade that took place back on Dec 30 ’24, which means that Vaddi Krishna is holding 137,553 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for PRLD
Current profitability levels for the company are sitting at:
- -22.3 for the present operating margin
- 0.81 for the gross margin
The net margin for Prelude Therapeutics Inc stands at -20.47. The total capital return value is set at -0.82. Equity return is now at value -66.64, with -57.72 for asset returns.
Based on Prelude Therapeutics Inc (PRLD), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -5.83. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -102.55.
Currently, EBITDA for the company is -131.11 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 7.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.04.
Conclusion
In conclusion, Prelude Therapeutics Inc (PRLD) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
